recurrent nsclc
Showing 1 - 5 of 5
NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)
Not yet recruiting
- Non-small Cell Lung Cancer
- +32 more
- (no location specified)
Mar 30, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)
Active, not recruiting
- NSCLC Stage IIIB
- +4 more
-
Hong Kong, Hong Kong
- +8 more
Jan 10, 2023
Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer Trial in Nanjing (Sintilimab + Anlotinib +
Recruiting
- Metastatic NSCLC
- +2 more
- Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
- Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Aug 10, 2021
Advanced NSCLC, Recurrent NSCLC Trial in Tianjin (Endostar(rh recombinant endostatin) plus Docetaxel, Placebo plus Docetaxel)
Unknown status
- Advanced NSCLC
- Recurrent NSCLC
- Endostar(rh recombinant endostatin) plus Docetaxel
- Placebo plus Docetaxel
-
Tianjin, ChinaCancer Hospital of Tianjin Medical University
Jan 22, 2010